East Brunswick

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Gastric and oesophageal cancer2 trials
• Prostate cancer2 trials
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Head and neck cancer1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Multiple myeloma1 trial
• Ovarian cancer1 trial

Phase

• Phase 34 trials
• Phase 1/21 trial
• Phase 21 trial

Status

• Recruiting3 trials
• Active, not recruiting1 trial
• Not yet recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• AstraZeneca6 trials

Running trials

• Recruiting

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· Phase 3· AstraZeneca· Source

• Recruiting

  First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

  NCT07529717· Phase 1/2· AstraZeneca· Source

• Recruiting

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· Phase 3· AstraZeneca· Source

• Recruiting

  Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  NCT05489211· Phase 2· AstraZeneca· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

  NCT05211895· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer2 recruiting
• Prostate cancer2 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Recruiting

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· Phase 3· AstraZeneca· Source